116247-98-4

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(4-FLUORO-PHENYL)-PIPERIDIN-4-ONE is used as a key intermediate in the synthesis of various pharmaceuticals and organic compounds, contributing to the development of new drugs and chemical entities.
Used in Neurological Disorders Treatment:
In the medical field, 1-(4-FLUORO-PHENYL)-PIPERIDIN-4-ONE is used as a potential therapeutic agent for the treatment of neurological disorders, leveraging its pharmacological properties as a dopamine receptor antagonist.
Used in Research and Development:
1-(4-FLUORO-PHENYL)-PIPERIDIN-4-ONE is utilized in research settings to investigate its potential applications and to understand its pharmacological effects, which can lead to the creation of new chemical entities with specific therapeutic targets.

InChI:InChI=1/C11H12FNO/c12-9-1-3-10(4-2-9)13-7-5-11(14)6-8-13/h1-4H,5-8H2

Upstream product

• 460-00-4 1-Bromo-4-fluorobenzene 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 3592-25-4 1,5-dichloropentan-3-one 
• 371-40-4 4-fluoroaniline 

Downstream Products

• 1160787-01-8 methyl 2-(4-fluorophenyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole-8-carboxylate 
• 1244027-32-4 1-(4-fluorophenyl)-6'-(5-methyl-1H-pyrazol-4-yl)-1'H-spiro[piperidine-4,2'-thieno[3,2-d]pyrimidin]-4'(3'H)-one 
• 1259380-41-0 1-(4-fluorophenyl)-7'-methoxy-5'H-spiro[piperidine-4,4'-pyrrolo[1,2-a]quinoxaline] hydrochloride 
• 1192165-71-1 [1-(4-fluorophenyl)-4-methylpiperidin-4-yl]acetonitrile 
• 1192165-70-0 ethyl cyano[1-(4-fluorophenyl)-4-methylpiperidin-4-yl]acetate 
• 1235971-77-3 1-(4-fluoro-benzyl)-4-[1-(4-fluoro-phenyl)-piperidin-4-yl]-piperazine 
• 1070894-63-1 8-(4-fluorophenyl)-4-(cyclohexylamino)-1-(3-fluorophenyl)-1,3,8-triazaspiro[4.5]dec-3-en-2-one 

Relevant academic research and scientific papers

Effect of through-bond interaction on conformation and structure in rod-shaped donor - acceptor systems: Part 1. Crystal structures of five N-arylpiperidin-4-one derivatives

The crystal structures of five N-arylpiperidin-4-one derivatives 2P2, 3P2, 5P2, 1P3, and 2P3 are presented (Fig. 2 and Tables 1-5) and discussed together with the derivatives 1P2 and 4P2 published previously. In all but one structure, 1P2, the aryl group is in an equatorial position. The piperidine ring adopts a normal chair conformation. In 1P2, the piperidine ring central C-C bonds are significantly elongated, which is consistent with the idea that through-bond interaction is more pronounced in the axial conformation. Through-bond interaction also influences the pyramidalization at the piperidine C(4)-atom in such a way that a strong interaction is directing the ethylene C-atom C(9) into the axial direction.

An improved synthesis of N-aryl and N-heteroaryl substituted piperidones

An efficient Pd(0)-catalyzed protocol for the rapid and efficient preparation of N-aryl and N-heteroaryl substituted piperidones is described. The two step syntheses proceed with an overall yield of 50-70% using X-Phos as optimal ligand for the Pd(0)-cata

5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND

The present invention provides compounds which promote erythropoietin production. Compounds represented by the following general formula (1) or pharmacologically acceptable salts thereof are provided: [wherein, R1 represents a group —X-Q1, X-Q1-Y-Q2 or X-Q1-Y-Q2-Z-Q3, X represents a single bond, —CH2— or the like, Q1 represents a monocyclic or bicyclic heterocyclic group which may have substituent(s), Y represents a single bond, —CH2—, or the like, Q2 represents a monocyclic or bicyclic hydrocarbon ring group which may have substituent(s) or a monocyclic or bicyclic heterocyclic group which may have substituent(s), Z represents a single bond, —CR11R12— or the like, R11 and R12 each independently represents a hydrogen atom, a halogen atom or the like, Q3 represents a phenyl group which may have substituent(s), a C3-C7 cycloalkyl group which may have substituent(s), a C3-C7 cycloalkenyl group which may have substituent(s) or a monocyclic or bicyclic heterocyclic group which may have substituent(s), R2 represents a C1-C3 alkyl group or the like, and R3 represents a hydrogen atom or a methyl group].

PIPERIDIN-4-YLPIPERAZINE COMPOUNDS FOR THE TREATMENT OF HCV INFECTION

The invention relates to new piperazine-pieridine compounds having anti-viral activity and particularly anti-HCV activity. The invention further relates to pharmaceutical compositions comprising compounds according to the invention.

Synthesis and exploratory photophysical investigation of donor-bridge-acceptor systems derived from N-substituted 4-piperidones

We report a two-step synthesis for N-aryl- and N-alkyl-substituted 4-piperidones, in which the N substituent can easily be varied.A number of intramolecular donor-acceptor systems was synthesized from these piperidones by conversion of the carbonyl functionality.The influence of the N-aryl donor on the electronic absorption and fluorescence spectra was investigated systematically.It was concluded that some systems can be used as efficient fluorescent probes with a high sensitivity for solvent polarity.